ESPR supply chain intelligence for Esperion Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PFE | Pfizer Inc. | 90% | In April 2008, we entered into an asset transfer agreement with Pfizer pursuant to which we acquired all intellectual property owned by Pfizer relating exclusively to the bempedoic acid program. |
| PFE | Pfizer Inc. | 90% | Reciprocal relationship from PFE graph: Reciprocal relationship from ESPR graph: In April 2008, we entered into an asset transfer agreement with Pfizer pursuant to which we acquired all intellectual … |
| ORANY | ORANY | 72% | . We maintain oversight of our vendors with access to our information technology resources through the inclusion of contractual security requirements as appropriate. Our cybersecurity approach is des… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from ESPR graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from ESPR graph: . We maintain oversight of our ve… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ESPR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ESPR graph: Reciprocal relationship from SNYN… |
| SNYNF | Sanofi | 72% | se of these systems. Likewise, in the U.S., several states, including Colorado and California, passed laws that will take effect in 2026, to regulate various uses of artificial intelligence, includin… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ATHYRIUM-OPPORTUNITIES-IV-ACQUISITION-LP | ATHYRIUM-OPPORTUNITIES-IV-ACQUISITION-LP | 92% | Pursuant to the Purchase Agreement, the Company sold to the Purchaser, and the Purchaser purchased for $50,000,000, a portion of the royalties payable to the Company |
| CORSTASIS | CORSTASIS | 92% | the equityholders of Corstasis will be entitled to receive: (i) milestone payments up to an aggregate amount equal to $180,000,000 in the event certain regulatory approval or commercial sales milesto… |
| SPECIALTY-PHARMACIES | SPECIALTY-PHARMACIES | 92% | The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies for NEXLETOL and NEXLIZET. The Company's net product sales are with these customers. |
| DAIICHI-SANKYO-EUROPE | DAIICHI-SANKYO-EUROPE | 90% | Daiichi Sankyo Europe, Esperion’s strategic partner across Europe, delivered double digit annual growth across key EU markets |
| HLS-THERAPEUTICS | HLS-THERAPEUTICS | 90% | HLS Therapeutics, Esperion’s strategic partner in Canada, announced NILEMDO ™ (bempedoic acid) is now available in Canada |
| DSE | DSE | 85% | On January 2, 2019, we entered into a license and collaboration agreement, or LCA, with DSE. Pursuant to the agreement, we have granted DSE exclusive commercialization rights to bempedoic acid and th… |
| NEOPHARM-ISRAEL | NEOPHARM-ISRAEL | 85% | Esperion continues to expect its partner in Israel, Neopharm Israel, to receive regulatory approval to market NEXLETOL and NEXLIZET in the first half of 2026 |
| CSL-SEQIRUS | CSL-SEQIRUS | 80% | CSL Seqirus, the Company’s partner in Australia and New Zealand, filed a marketing application in Australia for NEXLETOL and NEXLIZET in July 2025 |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from ESPR graph: ll receive tiered royalties of five percent ( %) to twenty percent ( %) of net sales in the DS Territory. F-17 Table… |
| ORANY | ORANY | 72% | ll receive tiered royalties of five percent ( %) to twenty percent ( %) of net sales in the DS Territory. F-17 Table of Contents Esperion Therapeutics, Inc. Notes to Financial Statements (Continued) … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ESPR graph: and commercialization objectives. We rely on consultants and advisors, including scientific and clinical advisors, t… |
| SNYNF | Sanofi | 72% | and commercialization objectives. We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization strategy. Our cons… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ESPR-DEBT-9364 | Warrants outstanding: 36964286 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| ESPR-DEBT-9365 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-03-31. |
| ESPR-DEBT | Debt stack $543.8M | 90% | Market cache reports total debt of $543.8M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ESPR-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 208 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| GRDX | GridAI Technologies Corp. | 100.00 | 2 |